PMID- 35845574
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231009
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Clinical Efficacy of Huangkui Capsule plus Methylprednisolone in the Treatment of 
      Nephropathy and the Effect on Urinary Protein and Serum Inflammatory Factors in 
      Patients.
PG  - 6232264
LID - 10.1155/2022/6232264 [doi]
LID - 6232264
AB  - OBJECTIVE: The study aimed to assess the clinical efficacy of Huangkui capsule 
      plus methylprednisolone in the treatment of nephropathy and the effect on urinary 
      protein and serum inflammatory factors in patients. METHODS: Between June 2017 
      and July 2020, 90 patients with nephropathy admitted to our hospital were 
      recruited after assessment of eligibility and assigned via the random number 
      table method (1 : 1) to receive either methylprednisolone tablets (observation 
      group) or methylprednisolone tablets plus Huangkui capsules (experimental group). 
      All eligible patients were also given dipyridamole and valsartan. Outcome 
      measures included clinical efficacy, urine protein, hematuria, serum inflammatory 
      factor levels, and adverse reactions. RESULTS: A higher clinical efficacy was 
      observed in the experimental group versus the observation group (P < 0.05). 
      Huangkui capsules resulted in significantly lower levels of urine protein and 
      hematuria in the experimental group versus the observation group after treatment 
      (P < 0.05). The serum tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and 
      monocyte chemoattractant protein-1 (MCP-1) levels in the experimental group were 
      significantly lower than those in the observation group after treatment (P < 
      0.05). Huangkui capsules plus methylprednisolone were associated with a lower 
      incidence of adverse events versus methylprednisolone (P < 0.05). CONCLUSION: The 
      clinical efficacy of Huangkui capsule plus methylprednisolone in the treatment of 
      patients with nephropathy is remarkable. It can effectively mitigate the 
      inflammatory responses and enhance renal function, with reliable clinical safety, 
      so it is worthy of clinical application.
CI  - Copyright (c) 2022 Weibo Wan et al.
FAU - Wan, Weibo
AU  - Wan W
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Zhou, Jingjing
AU  - Zhou J
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Lu, Rong
AU  - Lu R
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Wang, Chaoyang
AU  - Wang C
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Hu, Shuli
AU  - Hu S
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Liu, Mei
AU  - Liu M
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Xiong, Rong
AU  - Xiong R
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Kuang, Jing
AU  - Kuang J
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
FAU - Fan, Xuepeng
AU  - Fan X
AUID- ORCID: 0000-0003-0420-3254
AD  - Department of Critical Care, Wuhan First Hospital of Hubei Province, Wuhan 
      430000, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220706
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Sep 27;2023:9767505. PMID: 37808122
PMC - PMC9279028
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/19 06:01
PMCR- 2022/07/06
CRDT- 2022/07/18 03:51
PHST- 2022/04/12 00:00 [received]
PHST- 2022/06/08 00:00 [revised]
PHST- 2022/06/13 00:00 [accepted]
PHST- 2022/07/18 03:51 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/19 06:01 [medline]
PHST- 2022/07/06 00:00 [pmc-release]
AID - 10.1155/2022/6232264 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jul 6;2022:6232264. doi: 
      10.1155/2022/6232264. eCollection 2022.